A Fazekas score of 3 on a brain MRI report indicates severe and confluent lesions of the white matter. This grade, the highest on the Fazekas scale, reflects advanced damage to the small arteries in the brain. The question of life expectancy with Fazekas 3 leukoencephalopathy arises with particular urgency, as this stage significantly alters the medical strategy to be adopted.
Fazekas 3 and small vessel disease: a risk marker, not a death sentence
The hyperintensities of the white matter visible on MRI do not constitute a disease in itself. They indicate chronic vascular suffering at the level of the myelin, the protective sheath of nerve fibers. A Fazekas 3 grade indicates that these lesions are extensive, with confluent areas occupying a significant portion of the deep white matter.
Recent synthesis work on small vessel disease positions these lesions as one of the most powerful markers of future risk for stroke, dementia, and mortality. This finding holds true even when lesions are discovered incidentally on an MRI performed for another reason, in a person without major symptoms.
To delve deeper into life expectancy with Fazekas 3 leukoencephalopathy, it is essential to understand that this grade does not predict a precise lifespan on its own. It depends on age, comorbidities, the level of control of vascular risk factors, and the presence or absence of associated cognitive or motor symptoms.
A report from the Japan Brain Dock Society (2023-2024) suggests considering a Fazekas 3 score as a signal to revisit the overall vascular risk of the patient. The goal is to move from a passive reading of the MRI to an active intervention on modifiable factors.
Fazekas 3 brain lesions and the risk of vascular dementia: what the data shows
The link between high lesion load in the white matter and cognitive decline is documented. Individuals with a Fazekas 3 score have an increased risk of developing vascular dementia or mixed dementia (vascular and degenerative). This risk increases when other markers of small vessel disease are present: brain lacunae, microbleeds, cortical atrophy.
The available data do not allow for a definitive timeframe between the appearance of a Fazekas 3 score and the development of dementia. Progression varies significantly from one individual to another. Some individuals maintain relatively preserved cognitive functions for years, while others experience a more rapid decline.
Uncontrolled hypertension remains the most documented accelerating factor. Diabetes, dyslipidemias, and smoking also worsen the trajectory. In contrast, patients whose blood pressure is strictly controlled show a slower progression of lesions on follow-up MRIs.
Associated disorders at Fazekas 3 stage
Beyond the risk of dementia, a Fazekas 3 score may be accompanied by symptoms that impair quality of life without necessarily threatening short-term survival:
- Gait and balance disorders, with an increased risk of falls, related to damage to subcortical motor circuits
- Slowed information processing and concentration difficulties, often confused with normal aging
- Urinary disorders (urinary urgency), related to disconnection between the bladder control centers and the frontal cortex
- Mood changes, particularly apathy and depressive syndrome, common in frontal vascular lesions
These disorders do not all occur simultaneously. Their onset and intensity depend on the precise location of the lesions and the brain’s ability to compensate for the damaged areas.
Control of vascular risk and multifactorial interventions: concrete levers
The management of Fazekas 3 leukoencephalopathy does not rely on a single treatment targeting the lesions themselves. No medication repairs already damaged white matter. The strategy aims to slow progression and reduce the risk of serious vascular events.
Intensive control of blood pressure is the central pillar. Recent recommendations from cardiology and neurology societies converge on this point: maintaining strict blood pressure targets reduces the progression of white matter hyperintensities on follow-up MRIs.
Multifactorial lifestyle interventions
Clinical trials on combined interventions (physical activity, diet, cognitive stimulation, cardiovascular risk management) suggest a positive effect on slowing brain aging. These approaches do not specifically target leukoencephalopathy but act on the underlying vascular mechanisms.
- Regular adapted physical activity: improvement of cerebral perfusion and reduction of arterial stiffness, two parameters directly related to lesion progression
- Rigorous glycemic control in diabetic patients, as diabetes accelerates microvascular brain damage
- Smoking cessation, an independent factor in the progression of small vessel disease
Regular MRI follow-up allows for measuring the evolution of the lesion load and adjusting the therapeutic strategy. A follow-up examination every one to two years is generally proposed for patients with a Fazekas 3 score.
Neurological follow-up and the role of the primary care physician in the face of severe leukoencephalopathy
The neurologist remains the reference specialist for interpreting the lesions and assessing their functional impact. A neuropsychological assessment allows for objectively quantifying potential cognitive disorders and distinguishing decline related to vascular leukoencephalopathy from other causes of dementia.
The primary care physician plays a coordinating role on a daily basis. They adjust antihypertensive treatments, monitor metabolic factors, and refer to specialists in case of new symptoms. The early detection of a silent lacunar stroke, common in small vessel disease, often relies on this vigilance in outpatient medicine.
The question of life expectancy is not reduced to a number. It depends on the severity of the lesions, the quality of vascular control, and the cognitive reserve of each patient.
A Fazekas 3 score requires active and prolonged management, but it does not condemn one to rapid or inevitable decline. Some patients stabilize their lesions for several years through rigorous management of their risk factors.
